Rozlytrek (entrectinib)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Rozlytrek (entrectinib), covering 2025-10-20 to 2026-03-06. Get the full timeline:
Most recent: Clinical Trial Update: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) [Phase 2]